Selected article for: "active infection and acute respiratory syndrome infection"
Author: Laouan Brem, Falmata; Rasras, Hammam; El Ouafi, Noha; Bazid, Zakaria
Title: Bilateral Pulmonary Embolism in Patients Recovered From Asymptomatic COVID-19 Infection
  • Cord-id: vbq3ox25
  • Document date: 2021_3_12
    • ID: vbq3ox25
    Snippet: Hypercoagulability state is common in patients with coronavirus disease 2019 (COVID-19), especially those requiring intensive care. Indeed, anticoagulation therapy is recommended for all hospitalized COVID-19-patients. Despite well-conducted thromboprophylaxis, so many patients have developed these life-threatening complications. However, these thrombotic events are not known to occur in asymptomatic COVID-19 patients or in those recovered from active severe acute respiratory syndrome coronaviru
    Document: Hypercoagulability state is common in patients with coronavirus disease 2019 (COVID-19), especially those requiring intensive care. Indeed, anticoagulation therapy is recommended for all hospitalized COVID-19-patients. Despite well-conducted thromboprophylaxis, so many patients have developed these life-threatening complications. However, these thrombotic events are not known to occur in asymptomatic COVID-19 patients or in those recovered from active severe acute respiratory syndrome coronavirus 2 infection. This case series of a bilateral pulmonary embolism that occurred in patients recovered from asymptomatic COVID-19 highlights the questions about extending thromboprophylaxis in ambulatory patients with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • active sars infection and low molecular weight: 1
    • active sars infection and low molecular weight heparin: 1
    • active sars infection and lung involvement: 1, 2
    • activity relationship and low molecular weight: 1, 2
    • admission day and low molecular weight: 1, 2, 3, 4, 5, 6, 7
    • admission day and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
    • admission day and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • admission day and lung involvement percentage: 1, 2
    • low molecular weight and lung involvement: 1, 2, 3, 4
    • low molecular weight heparin and lung involvement: 1, 2, 3, 4